Novo Nordisk A/S (NYSE:NVO) is one of the Best Value Stocks to Buy for the Long Term. On March 2, Novo Nordisk A/S (NYSE:NVO) announced a €432 million (DKK 3.2 billion) investment in its Monksland facility in Athlone, Ireland, to boost production of oral GLP-1 treatments.
Management noted that this investment will allow the company to have a hub to serve international markets outside of the US. The investment is aimed at retrofitting the existing tableting plant, adding capacity for current and future GLP-1 drugs like oral Semaglutide. The company has already started construction on the 45-acre site and is expected to wrap up gradually from late 2027 to 2028.
Management also highlighted that the already recruited 260 employees at the site are expected to prioritize high-quality, sustainable oral treatments, while the construction is projected to create up to 500 jobs. Kasper Bødker Mejlvang, EVP CMC & Product Supply of the company, called it a “historic milestone” for Ireland operations and meeting patient needs for chronic diseases.
20 Countries with the Most Expensive Healthcare in the World
Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.
While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Follow Insider Monkey on Google News.